0001104659-26-081559.txt : 20260708 0001104659-26-081559.hdr.sgml : 20260708 20260708070053 ACCESSION NUMBER: 0001104659-26-081559 CONFORMED SUBMISSION TYPE: SCHEDULE 13D/A PUBLIC DOCUMENT COUNT: 3 FILED AS OF DATE: 20260708 DATE AS OF CHANGE: 20260708 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Silence Therapeutics plc CENTRAL INDEX KEY: 0001479615 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: X0 FILING VALUES: FORM TYPE: SCHEDULE 13D/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-92205 FILM NUMBER: 261160748 BUSINESS ADDRESS: ADDRESS IS A NON US LOCATION: YES STREET 1: 12 HAMMERSMITH GROVE STREET 2: OFFICE 205 CITY: LONDON PROVINCE COUNTRY: X0 ZIP: W6 7AP BUSINESS PHONE: 44-0-20-3457 6900 MAIL ADDRESS: ADDRESS IS A NON US LOCATION: YES STREET 1: 12 HAMMERSMITH GROVE STREET 2: OFFICE 205 CITY: LONDON PROVINCE COUNTRY: X0 ZIP: W6 7AP FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: Griffiths Richard Ian CENTRAL INDEX KEY: 0001846370 ORGANIZATION NAME: FILING VALUES: FORM TYPE: SCHEDULE 13D/A MAIL ADDRESS: ADDRESS IS A NON US LOCATION: YES STREET 1: C/O SILENCE THERAPEUTICS INC. STREET 2: 72 HAMMERSMITH ROAD CITY: LONDON PROVINCE COUNTRY: X0 ZIP: W14 8TH SCHEDULE 13D/A 1 primary_doc.xml X0202 SCHEDULE 13D/A 0001564590-22-023327 0001846370 XXXXXXXX LIVE 10 Ordinary Shares, nominal value of PS0.05 per share 07/06/2026 false 0001479615 G8128Y157 Silence Therapeutics Plc
72 Hammersmith Road London X0 W14 8TH
Richard Griffiths 44 1534 517500 19-21 Broad Street St Helier Y9 JE2 3RR 0001846370 N Richard Griffiths PF N Y9 30844458.00 0.00 30844458.00 0.00 30844458.00 N 21.7 IN * Consists of (i) 19,155,522 ordinary shares represented by American Depositary Shares ("ADSs") held by Ora Capital Limited; (ii) 1,815,522 ordinary shares represented by ADSs held by Sarossa Plc; (iii) 3,000,000 ordinary shares represented by ADSs held by Cream Capital Limited; ; (iv) 300,000 ordinary shares represented by ADSs held by Blake Holdings Limited; (v) 360,000 ordinary shares represented by ADSs held by Ora Ventures Limited; (vi) 190,500 ordinary shares represented by ADSs held by Pinkey's Limited; and (vii) 6,022,914 ordinary shares represented by ADSs held by Mr. Griffiths. Each ADS represents, and at the holder's option is convertible into, three ordinary shares of the Issuer. Mr. Griffiths is a director and the controlling shareholder of each of Ora Capital Limited, Ora Ventures Limited, Blake Holdings Limited, Sarossa Plc and Cream Capital Limited and a controlling shareholder of Pinkey's Limited and possesses the power to direct the voting and disposition of these shares. **This percentage is calculated based upon the 141,701,847 outstanding ordinary shares of the Issuer, as disclosed in the Issuer's last SEC filing. Y Ora Capital Limited WC N Y9 19155522.00 0.00 19155522.00 0.00 19155522.00 N 13.5 CO * Consists of 19,155,522 ordinary shares represented by ADSs held by Ora Capital Limited. **This percentage is calculated based upon the 141,701,847 outstanding ordinary shares of the Issuer, as disclosed in the Issuer's last SEC filing. Ordinary Shares, nominal value of PS0.05 per share Silence Therapeutics Plc 72 Hammersmith Road London X0 W14 8TH This Amendment No. 10 to Schedule 13D (this "Amendment"), which amends and supplements the Schedule 13D filed with the Securities and Exchange Commission (the "SEC") on June 15, 2022, as amended on July 20, 2022, October 20, 2022, August 14, 2023, March 27, 2024, December 18, 2024, March 31, 2025, April 24, 2025, May 8, 2025 and June 25, 2025 (the "Schedule 13D") on behalf of Richard Ian Griffiths, relates to the ordinary shares, nominal value PS0.05 per share (the "Shares"), of Silence Therapeutics plc (the "Issuer"). This Amendment is being filed to reflect the open market transactions of the Issuer's ADSs by the Reporting Person together with dilution as a result of an increase in the share capital of the Issuer. Except as amended and supplemented hereby, the Schedule 13D remains in full force and effect. All capitalized terms used in this Amendment but not defined herein shall have the meanings ascribed thereto in the Schedule 13D. Richard Griffiths 19-21 Broad Street, St Helier, Jersey, JE2 3RR n/a n/a Jersey, Channel Islands Mr. Griffiths sold an aggregate of 1,544,374 ADSs in open market transactions between June 29, 2026 and July 6, 2026 for aggregate sales proceeds of $16.3M. n/a A. Joint Filing Agreement as required by Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended. B. Schedule 1 Transactions in ADSs During the Past Sixty Days Richard Griffiths /s/ Richard Ian Griffiths Richard Ian Griffiths 07/07/2026 Ora Capital Limited /s/ Richard Ian Griffiths Director 07/07/2026 EX-99.A 2 tm2619944d1_ex99-a.htm EXHIBIT A

 

EXHIBIT A

 

JOINT FILING AGREEMENT

 

The undersigned hereby agree that a single Schedule 13D (or any amendment thereto) relating to the Ordinary Shares of Silence Therapeutics plc shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to such Schedule 13D.

 

Date: June 25, 2025

 

Ora Capital Limited 
   
By:/s/ Richard Ian Griffiths 
 Name: Richard Ian Griffiths 
 Title: Director 

 

Richard Ian Griffiths 
   
/s/ Richard Ian Griffiths 

 

 

 

 EX-99.B 3 tm2619944d1_ex99-b.htm EXHIBIT B

 

Exhibit 99.b

 

Schedule 1

 

Transactions in ADSs past 60 days to 7 July 2026

 

Date Nature of the
Transaction		 Reporting Person Amount of Securities
Purchased/Sold		 Price
06/29/26 Sale Richard Griffiths 330,072 $10.69
06/30/26 Sale Richard Griffiths 169,928 $10.76
07/01/26 Sale Richard Griffiths 79,180 $10.62
07/01/26 Sale Richard Griffiths 50,000 $10.62
07/02/26 Sale Richard Griffiths 50,082 $10.47
07/06/26 Sale Cream Capital Limited 865,112 $10.53